{"analyses":[{"ciLowerLimit":"0.43","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.78","estimateComment":"Stratified by randomization stratification factors: PD-L1 Status (\\>=1% vs \\<1%/not evaluable/indeterminate), disease stage (II vs III), histology (squamous vs non-squamous).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00025","paramType":"Cox Proportional Hazard","paramValue":"0.58","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Insufficient number of participants with events","groupId":"OG000","lowerLimit":"28.94","value":"NA"},{"groupId":"OG001","lowerLimit":"13.63","upperLimit":"28.06","value":"18.43"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"229"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"The length of time from randomization to any of the following events: progression of disease or worsening of disease precluding surgery, if surgery is attempted but gross resection is abandoned due to unresectable tumor or worsening of disease, progression or recurrence of disease after surgery, progression or recurrence of disease without surgery, or death due to any cause. Progression/recurrence will be assessed by BICR per RECIST 1.1. Participants who do not undergo surgery for reason other than progression will be considered to have an event at RECIST 1.1 progression or death","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 360 mg Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery; then post surgery nivolumab 480 mg Q4W adjuvant treatment for up to 13 cycles (approximately 1 year)","id":"OG000","title":"Nivolumab + SOC Chemotherapy"},{"description":"Placebo Q3W + SOC platinum-based doublet chemotherapy Q3W x 4 cycles as neoadjuvant treatment followed by surgery, then post-surgery placebo Q4W for up to 13 cycles (approximately 1 year).","id":"OG001","title":"Placebo + SOC Chemotherapy"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression, worsening, recurrence, or death due to any cause (up to approximately 44 months)","title":"Event-Free Survival (EFS) by BICR","type":"PRIMARY","unitOfMeasure":"Months"}